Association Between Increased Mortality and Mild Thyroid Dysfunction in Cardiac Patients by G. IERVASI et al.
ORIGINAL INVESTIGATION
Association Between Increased Mortality
and Mild Thyroid Dysfunction in Cardiac Patients
Giorgio Iervasi, MD; Sabrina Molinaro, PhD; Patrizia Landi, BSc; Maria Chiara Taddei, BSc;
Elena Galli, MD; Fabio Mariani, PhD; Antonio L’Abbate, MD; Alessandro Pingitore, MD, PhD
Background: The effects of subclinical thyroid dys-
function on cardiac outcome are not well defined.
Methods: To assess the relationship between mild thy-
roid dysfunction and the incidence of death in cardiac
patients, we evaluated 3121 cardiac patients. Cardiac and
overall deaths were considered. Four groups were de-
fined: euthyroidism, subclinical hypothyroidism (SCH),
subclinical hyperthyroidism (SCT), and low triiodothy-
ronine syndrome (low T3).
Results:After mean follow-up of 32months, there were
65 and 140 cardiac and overall deaths (3.4% and 7.3%),
respectively, in euthyroidism, 15 and27 (7.2%and13.0%)
in SCH, 8 and 9 (8.2% and 9.2%) in SCT, and 59 and
119 (6.5% and 13.1%) in low T3. Survival rates for car-
diac death were lower in SCH, SCT, and low T3 than in
euthyroidism (log-rank test; ²=19.46; P .001). Sur-
vival rates for overall death were lower in SCH and low
T3 than in euthyroidism (log-rank test; ² =26.67;
P .001). After adjustment for several risk factors, haz-
ard ratios (HRs) for cardiac death were higher in SCH
(HR, 2.40; 95% confidence interval [CI], 1.36-4.21;
P=.02), SCT (HR, 2.32; 95% CI, 1.11-4.85; P=.02), and
low T3 (HR, 1.63; 95% CI, 1.14-2.33; P=.007) than in
euthyroidism; HRs for overall death were higher in SCH
(HR, 2.01; 95%CI, 1.33-3.04; P .001) and low T3 (HR,
1.57; 95% CI, 1.22-2.01; P .001) but not in SCT.
Conclusion: A mildly altered thyroid status is associ-
ated with an increased risk of mortality in patients with
cardiac disease.
Arch Intern Med. 2007;167(14):1526-1532
C ARDIOVASCULAR DISEASE ISthe foremost cause of pre-mature death in men andwomen inWestern coun-tries; these diseases also
have amajor impact onhealth care and can
be a great economic burden, being the
most common cause of hospital admis-
sion.1 At the same time, the death rate for
cardiovascular disease has been declin-
ing in the past few years. Strategies for re-
ducing risk factors have unequivocally
played an important role in reducingmor-
tality and morbidity rates, especially in
peoplewith recognized cardiovascular dis-
ease.1,2 Attention has particularly fo-
cused on discovering new, potentially im-
portant risk factors. In population-based
studies,3-9 the effects of mild thyroid dys-
function on cardiovascular outcome are in-
creasingly emerging but are not yet well
defined. A low triiodothyronine syn-
drome (low T3) has been related to a poor
outcome in different groups of cardiac pa-
tients.10-12 Data on the prognostic impact
of mild thyroid dysfunction in patients
with cardiac disease are, however, lim-
ited and somewhat conflicting.13-15 In this
context, no increase in cardiovascular
death has been reported by Rodondi et al13
and Cappola et al.14 An association be-
tween increased reverse triiodothyronine
levels andmortalitywas found, on the con-
trary, after acute myocardial infarction.15
This large prospective study tests the hy-
pothesis that a mildly altered thyroid sta-
tus is associated with an increased risk of
mortality in patients with diagnosed is-
chemic or nonischemic cardiac disease.
METHODS
STUDY POPULATION
Atotalof4368patientswereadmittedtotheCar-
diology Department of the National Research
Council InstituteofClinical Physiology inPisa,
Italy, between January 1, 2000, and January 1,
2006. The study’s exclusion criteria were as
follows: (1) emergency admissions for acute
coronary syndrome or pulmonary edema (563
patients); (2) severely ill patients, that is, with
clinical evidence of sepsis or cachexia or the
concomitant presence of any predominant se-
vere systemic disease (50 patients); (3) in-hos-
pital deaths (42 patients); (4) primary overt
hypothyroidism (thyrotropin level10mIU/L
and free thyroxine level0.71 ng/dL [to con-
vert topicomoles per liter,multiply by12.871])
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(15 patients); (5) primary overt hyperthyroidism (free triio-
dothyronine level420pg/dL [to convert to picomoles per liter,
multiply by 0.0154] or free thyroxine level1.85 ng/dL, with
an undetectable thyrotropin level) (31 patients); (6) concomi-
tant treatment with synthetic thyroid hormones, antithyroid
drugs, corticosteroids, dopamine, dobutamine, or amiodarone
(262 patients); and (7) atypical thyroid status, inwhich the thy-
roidhormonepatterncouldnotbeclustered inanydefinedgroup
after the first hormone evaluation (97 patients) or the thyroid
hormone patternmodified at repeated thyroid function testing
(187 patients) (see “Definition of Thyroid Status” subsection
herein). Thus, the final population consisted of 3121 consecu-
tive patients (32.6% female; mean age, 61 years) routinely
admitted for evaluation and diagnosed as having heart disease.
During hospitalization all the patients underwent conven-
tional noninvasive and, if necessary, invasive diagnostic pro-
cedures for the characterization of heart disease and related risk
factors according to international guidelines. Baseline data, in-
cluding blood pressure and blood determinations, were col-
lected at the time of hospitalization (Table 1). The diagnosis
of cardiac disease was based on data collected during hospi-
talization; previous cardiac diseases were defined according to
patients’ documentation of their cardiac history. Blood pres-
sure was measured twice at admittance according to a stan-
dardized protocol; Table 1 gives the mean value of the 2 mea-
sures.Hypertensionwasdefinedas systolicbloodpressuregreater
than 140 mm Hg or diastolic blood pressure greater than 90
mmHg.Diabetesmellituswas defined as a fasting glucose level
greater than 126mg/dL (to convert tomillimoles per liter,mul-
tiply by 0.0555) or the use of insulin or an oral hypoglycemic
drug.Weight and heightweremeasured in all the patients; obe-
sity was defined as a body mass index (calculated as weight in
kilograms divided by height in meters squared) greater than
30. The National Council of Research, Clinical Physiology In-
stitute ethics review committee approved the study, and the in-
vestigation conformed to the principles of the Declaration of
Helsinki.
THYROID HORMONE SAMPLING
The thyroid function profile was assessed in all the patients
within 2 to 5 days of hospital admission.11,12 After rapid cen-
trifugation of a blood sample collected at 7 AM from an ante-
cubital vein, free triiodothyronine, free thyroxine, and thyro-
tropin levels weremeasured immediately after the blood sample
Table 1. Baseline Characteristics of the Study Population by Thyroid Statusa
Characteristic
Euthyroidism
(n = 1905)
Subclinical
Hypothyroidism
(n = 208)
Subclinical
Hyperthyroidism
(n = 98)
Low T3
(n = 910)
Total
(N = 3121)
Age, y 59.9 (59.3-60.4) 60.9 (59.1-62.7) 60.5 (58.6-62.4) 63.8 (63.1-64.6)b 61.1 (60.7-61.5)
Female sex, No. (%) 548 (28.8) 89 (42.8) 45 (45.9)b 336 (36.9) 1018 (32.6)
Hypertension, No. (%)c 972 (51.0) 109 (52.4) 55 (56.1) 451 (49.6) 1587 (50.8)
Smoke, No. (%) 857 (45.0) 87 (41.8) 48 (49.0) 308 (33.8) 1300 (41.7)
Diabetes mellitus, No. (%) 363 (19.1) 51 (24.5) 21 (21.4) 206 (22.6) 641 (20.5)
History of coronary artery disease, No. (%) 869 (45.6) 89 (42.8) 39 (39.8) 378 (41.5) 1375 (44.1)
NYHA functional class III-IV, No. (%) 189 (9.9) 32 (15.4)b 5 (5.1) 119 (13.1) 345 (11.1)
Obesity, No. (%) 1076 (56.5) 120 (57.7) 61 (62.2) 507 (55.7)b 1764 (56.5)
Thyrotropin, mIU/L 1.67 (1.73-1.71) 6.7 (6.01-7.44) 0.15 (0.13-0.17) 1.66 (1.59-1.73) 1.96 (1.88-2.03)
Free triiodothyronine, pg/dL 252 (249-255) 231 (226-237) 266 (255-273) 183 (181-186) 231 (229-233)
Free thyroxine, ng/dL 1.17 (1.16-1.18) 1.10 (1.05-1.14) 1.39 (1.34-1.45) 1.23 (1.20-1.26) 1.19 (1.17-1.20)
Total cholesterol, mg/dL 190 (188-192) 194 (188-200) 185 (175-194) 182 (179-185 188 (186-190)
LDL cholesterol, mg/dL 121 (119-123) 122 (117-127) 116 (108-125) 116 (113-118)b 120 (118-121)
HDL cholesterol, mg/dL 43.8 (43.2-44.4) 47.4 (45.6-49.2)b 43 (40.1-45.9) 42.5 (41.6-43.4) 43.8 (43.4-44.3)
Triglycerides, mg/dL 126 (123-130) 120 (109-130)b 129 (106-152) 118 (111-124)b 124 (121-127)
Creatinine, mg/dL 1.07 (1.04-1.09) 1.10 (1.00-1.21) 1.08 (0.98-1.19) 1.14 (1.11-1.20)b 1.10 (1.07-1.11)
C-reactive protein, mg/L 0.90 (0.81-0.99) 0.98 (0.73-1.23) 0.89 (0.57-1.20) 1.52 (1.24-1.81)b 1.08 (0.98-1.18)
Ejection fraction, % 53 (52.7-53.7) 50 (48-52) 52 (50-54) 51 (50-52) 52 (52-53)
Ischemic heart disease, No. (%) 998 (52.4) 104 (50.0) 46 (46.9) 531 (58.4)b 1679 (53.8)
Nonischemic dilated cardiomyopathy, No. (%) 229 (12.0)b 42 (20.2) 17 (17.3) 121 (13.3) 409 (13.1)
Arrhythmias, No. (%) 513 (26.9)b 72 (34.6) 32 (32.7) 268 (29.5) 885 (28.4)
Valvular heart disease, No. (%) 174 (9.1)b 34 (16.3) 9 (9.2) 113 (12.4) 330 (10.6)
Others, No. (%)d 37 (1.9) 7 (3.4) 1 (1.0) 29 (3.2) 74 (2.4)
ACE inhibitors, No. (%) 698 (36.6) 77 (37.0) 39 (39.8) 362 (39.8) 1176 (37.7)
-Blockers, No. (%) 829 (43.5) 86 (41.3) 33 (33.7) 426 (46.8) 1374 (44.0)
Nitrates, No. (%) 839 (44.0) 76 (36.5) 40 (40.8) 433 (47.6)b 1388 (44.5)
Calcium antagonists, No. (%) 278 (14.6) 24 (11.5) 16 (16.3) 126 (13.8) 444 (14.2)
Diuretics, No. (%) 491 (25.8) 73 (35.1) 37 (37.8)b 312 (34.3) 913 (29.3)
Abbreviations: ACE, angiotensin-converting enzyme; HDL, high-density lipoprotein; LDL, low-density lipoprotein; low T3, low triiodothyronine syndrome;
NYHA, New York Heart Association.
SI conversion factors: To convert cholesterol (HDL, LDL, and total) to millimoles per liter, multiply by 0.0259; C-reactive protein to nanomoles per liter, multiply
by 9.524; creatinine to micromoles per liter, multiply by 88.4; free thyroxine to picomoles per liter, multiply by 12.871; free triiodothyronine to picomoles per liter,
multiply by 0.0154; triglycerides to millimoles per liter, multiply by 0.0113.
aSee the “Definition of Thyroid Status” subsection of the “Methods” section for thyroid category definitions. Data are given as mean (95% confidence interval),
except where noted otherwise.
bP.05 by 2 test or t test.
cBlood pressure was measured after the patient was as relaxed as possible for several minutes, not talking, and seated comfortably. The reported value is the
mean of 2 measures in 2 minutes.
dHypertrophic cardiomyopathy, myocarditis, pericarditis, and endocarditis.
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was collected using a completely automated AIA 600 system
(Tosho Corp, Tokyo, Japan). The reference intervals were as
follows: free triiodothyronine, 210 to 420 pg/dL; free thyrox-
ine, 0.71 to 1.85 ng/dL; and thyrotropin, 0.30 to 4.5 mIU/L.
DEFINITION OF THYROID STATUS
Patients were divided into 4 groups: (1) euthyroid, with all cir-
culating levels of free triiodothyronine, free thyroxine, and thy-
rotropin in the reference range; (2) subclinical primary hypo-
thyroidism (SCH), with thyrotropin levels between 4.5 and 10
mIU/L and free triiodothyronine and free thyroxine levels in
the reference range; (3) subclinical primary hyperthyroidism
(SCT), with thyrotropin levels less than 0.3mIU/L and free tri-
iodothyronine and free thyroxine levels in the reference range;
and (4) lowT3, with free triiodothyronine levels below the lower
limit of the reference interval and free thyroxine and thyrotro-
pin levels in the reference range.7 Because of the multidisci-
plinary nature of the Clinical Physiology Institute, a team of
cardiologists, internal medicine specialists, and endocrinolo-
gists strictly collaborate, taking care of patients during hospi-
talization and follow-up. All patients with an altered thyroid
profile were evaluated by an endocrinologist. According to the
guidelines for the diagnosis andmanagement of subclinical thy-
roid disease, to exclude transient forms of thyroid dysfunc-
tion, thyroid function tests were repeated within 2 to 12
weeks.7,16,17 The main criteria to determine the timing of re-
peated testing were (1) recovery of good general clinical con-
ditions and (2) stable or normalized values of the main biohu-
moral/instrumental variables (in particular, blood cell count,
electrolytes, indexes of renal and liver function, indexes of
phlogosis, electrocardiogram, echocardiogram, and chest ra-
diograph). To define the nature of thyroid disease, patients also
underwent, when recommended for diagnostic purposes, ul-
trasound evaluation, thyroid scintigraphy, and thyroid auto-
antibody determination. All the initial and confirmatory thy-
roid testing datawere available to the endocrinologists examining
the patients and to the cardiologists caring for the patients at
the time of hospitalization. Because the benefits of treatment
have not yet been established for patients with subclinical thy-
roid dysfunction,7,16,17 treatment was not recommended at the
time of patient enrollment.
FOLLOW-UP
Follow-up started the day of thyroid hormone evaluation (mean
duration, 32 months). Follow-up data were obtained semian-
nually from at least 1 of the following 4 sources: patient hos-
pital records, the patient’s physician, patient telephone inter-
views by trained personnel, and periodic examination of the
patient in the outpatient setting.11 Follow-up was censored at
initiation of therapy with synthetic thyroid hormones or anti-
thyroid drugs during follow-up.
The events considered were cardiac and overall deaths. In-
formation about deathswas obtained fromdeath certificates com-
peted by a medical officer in 137 cases (90.1%) and by medical
or autopsy reports in15cases (9.9%).Cardiacdeath requireddocu-
mentation of (1) arrhythmia or cardiac arrest, (2) death due to
progressive heart failure, or (3) myocardial infarction in the ab-
sence of a precipitating factor. Suddenunexpecteddeathwas clas-
sified as a cardiac deathwhen it occurred outside the hospital and
was not followed by an autopsy. Overall deaths were considered
all deaths fromanynatural cause.Deaths causedby accidentswere
excluded (follow-up censored at the time of death).
STATISTICAL ANALYSIS
Parametric and nonparametric data are given as mean±SD and
percentage. Groups were compared using the 2 test (Yates cor-
rection) and the unpaired t test. All the tests were 2-sided, and
P .05was considered statistically significant.UnivariateCox re-
gression analysiswas used to determinewhich variables (age, sex,
New York Heart Association functional class, ejection fraction,
ischemic heart disease, nonischemic dilated cardiomyopathy, ar-
rhythmias, valvular heart disease, angiotensin-converting en-
zyme inhibitors, -blockers, nitrates, calcium antagonists, di-
uretics, and levels of thyrotropin, free triiodothyronine, free
thyroxine, total cholesterol, high- and low-density lipoprotein cho-
lesterol, triglycerides, creatinine, and C-reactive protein) might
have predicted cardiac-related death and overall death. To ad-
just for several risk factors, multivariate Cox analysis was per-
formed, with all the variables found to be significant in univari-
ate analysis entered in a single step (age, sex, ischemic and
nonischemic cardiac disease, and thyroid status). During fol-
low-up the risks of cardiac-related death and all causes of death
were evaluated using Cox proportional hazards and the Kaplan-
Meiermodel. The hazard ratios (HRs) related to the different thy-
roid statuses of patientswere assessed, controlling for other prog-
nostic risk factors. TheKaplan-Meier life-tablemethod, estimating
cardiac-related death and overall death, was used to summarize
the follow-up experience in the patient population. Differences
in survival curves were tested using the log-rank test (Mantel-
Cox), adjusting for prognostic risk factors; P .05 was consid-
ered statistically significant.
Table 2. Survival Data for Cardiac and Overall Deaths by Thyroid Statusa
Variable
Euthyroidism
(n = 1905)
Subclinical
Hypothyroidism
(n = 208)
Subclinical
Hyperthyroidism
(n = 98)
Low T3
(n = 910)
²
Valueb
P
Value
Cardiac death
Death by AMI, No. 36 9 5 37
Sudden death, No. 12 3 2 18
Other causes of death, No. 17 3 1 4 19.46 .001
Subtotal, No. (%) 65 (3.4) 15 (7.2) 8 (8.2) 59 (6.5)
Survival time, mean (95% CI), d 2278 (2254-2302) 1973 (1889-2058) 1940 (1873-2042) 2202 (2160-2243)
Overall death
Events, No. (%) 140 (7.3) 27 (13.0) 9 (9.2) 119 (13.1)
26.67 .001Survival time, mean (95% CI), d 2167 (2130-2204) 1853 (1750-1955) 1923 (1817-2029) 2047 (1992-2102)
Abbreviations: AMI, acute myocardial infarction; CI, confidence interval; low T3, low triiodothyronine syndrome.
aSee the “Definition of Thyroid Status” subsection of the “Methods” section for thyroid category definitions.
bDetermined using the log-rank test.
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RESULTS
BASELINE CHARACTERISTICS
After initial hormone evaluation 3308 patients were
divided into the following groups: euthyroid, 1905
patients; SCH, 218 patients; SCT, 138 patients; and low
T3, 1047 patients. Repeated thyroid function tests
(mean time from first evaluation, 34 days; 95% confi-
dence interval, 22.8-42.2 days) gave confirmatory
results in 1905 euthyroid patients (100.0%), 208 SCH
patients (95.4%), 98 SCT patients (71.0%), and 910 low
T3 patients (86.9%); the remaining patients (n=187)
were excluded from the study. Clinical and hormonal
data at baseline are reported in Table 1.
The cause of the SCH was atrophic thyroiditis in 81
patients (38.9%), Hashimoto thyroiditis in 74 (35.6%),
and iatrogenic chronic hypothyroidism (ie, after partial
thyroidectomy or after sodium iodide I 131 therapy) in
53 (25.5%). The cause of the SCTwasmultinodular goi-
ter in 79 patients (80.6%), Graves disease in 15 (15.3%),
and thyroid adenoma in 4 (4.1%).
CARDIAC AND OVERALL MORTALITY
BY THYROID STATUS
There were 65 cardiac deaths in the euthyroid group, 15
in the SCH group, 8 in the SCT group, and 59 in the low
T3 group; the distribution of specific causes of cardiac
death did not differ in the 4 groups (Table 2). There
were 140 overall deaths in the euthyroid group, 27 in the
SCH group, 9 in the SCT group, and 119 in the low T3
group (Table 2). Regarding cardiac death, Kaplan-
Meier mean survival time was significantly longer for the
euthyroid group than for the other 3 groups (log-rank
test; ²=19.46; P .001). Mean survival time was sig-
nificantly shorter in SCH and low T3 than in euthyroid-
ism (log-rank test; ²=26.67; P .001) (Table 2 and the
Figure). When the relationship between thyroid status
and cardiac and overall deaths was assessed using Cox
proportional hazards regression and modeling strate-
gies in adjusted analyses, the HR of cardiac deathwas sig-
nificantly higher in the last 3 groups than in the euthy-
roid group (Table 3). Compared with euthyroidism, the
HR of overall death was significantly higher in SCH and
low T3 but not in SCT.
When patients were subdivided according to ische-
mic (n=1679) and nonischemic (n=1442) heart dis-
ease, the HR for cardiac death in patients with ischemic
heart disease was significantly higher in SCT, SCH, and
low T3 than in euthyroidism (Table 4).
COMMENT
The major finding of this large prospective observa-
tional study was that the concomitant presence of an
unknown mild thyroid dysfunction is linked to an
increased risk of mortality in patients with cardiac dis-
ease. Moreover, analysis of subgroups of patients (ie,
ischemic and nonischemic patients) showed that mild
thyroid dysfunction increased the risk of death particu-
larly in ischemic heart disease. These results have been
reached in a large population of patients with clinically
stable cardiac disease. In this study the prevalence of
SCH (6.6%), SCT (3.1%), and low T3 (29.2%) was in
close agreement with that reported in the literature
regarding the general population without known thy-
roid disease,7,11,13 thus confirming the suitability of the
criteria used and the classification of thyroid status
according to guidelines.7 At the same time, note that the
present data were obtained in a cohort of mainly male
patients. Thus, because subclinical thyroid disease
affects mostly women, we have to be very careful in giv-
ing direct applicability of the present results. Alto-
gether, the results of this observational prospective
study open the way to interesting pathophysiologic
interpretations. The observed negative prognostic
impact of any form of mild thyroid dysfunction in car-
diac patients reinforces the hypothesis that a normal
thyroid status is essential for maintaining systemic and
cardiovascular homeostasis5,6; when a normal thyroid
status is persistently lost, increased whole-body and
cardiovascular vulnerability is observed.
MILD HYPOTHYROIDISM
In this study the Kaplan-Meier curves showed a statisti-
cally significant increase in the incidence of cardiac and
overall deaths in patients with SCH compared with
euthyroid patients. This finding is further reinforced at
HR analysis, which showed that SCH is an independent
predictor of death. Several pathophysiologic studies18,19
have shown the presence of cardiovascular abnormali-
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Figure. Kaplan-Meier survival curves for cardiac death (A) and overall death
(B) by thyroid status. For cardiac death, P .001 for euthyroidism vs the
other 3 groups. For overall death, P .001 for euthyroidism vs subclinical
hypothyroidism and low triiodothyronine syndrome (low T3).
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ties in patients with SCH. Moreover, some population-
based studies9,20,21 provided evidence that SCH affects
serum cholesterol levels and increases atherosclerotic
processes. Whether SCH per se contributes to worsen-
ing cardiovascular outcome is still a debated issue. In
particular, 2 unresolved questions are whether SCH
increases the risk of cardiovascular disease in the gen-
eral population and whether it has a negative prognos-
tic impact in cardiac patients. Only a few health survey
population-based studies have attempted to answer the
first question, and results are somewhat contradictory.
Indeed, SCH was found to be associated with increased
risk of myocardial infarction in elderly women,15
increased overall death in men,22 increased risk of heart
failure in older adults,23 and more cardiovascular
events.24 The negative prognostic impact of SCH has
also been shown in a recent meta-analysis.13 In contrast
to the present results, Rodondi et al23 and Cappola et
al14 did not find any association between SCH and car-
diac mortality. One of the main differences with these
studies was that whereas the present findings were
obtained in a population of cardiac patients with a
mean age of 61 years, their data were obtained in a
population-based cohort of elderly (65 years) people.
Furthermore, in the present study the definition of
groups as SCH, SCT, low T3, and euthyroid was based
on simultaneous measurement of free triiodothyronine,
free thyroxine, and thyrotropin levels; this is at variance
with all the previously mentioned studies, in which thy-
rotropin and, when available, free thyroxine were used
for definition of the thyroid status. In the absence of tri-
iodothyronine data, patients with low T3 could have
been included in the euthyroid group; this inclusion
might have affected the cardiac end points owing to the
strong negative prognostic impact of low T3. The lack of
triiodothyronine data would have been particularly rel-
evant in studies in which elderly patients were
enrolled14 and in whom an altered thyroid hormone
peripheral metabolism can be a common feature.
MILD HYPERTHYROIDISM
The main finding of this study was that although mild
hyperthyroidism has no impact on overall mortality, it
represents an independent predictor of cardiac death
because the survival rate in SCT is significantly lower
than that in euthyroidism. The few studies14,24,25 that
have attempted to assess the effects of SCT on cardiac
outcome provided somewhat contrasting results. The
present data are not comparable with those of previous
studies for 2 main reasons: (1) as already observed for
mild hypothyroidism, the cited studies were population-
Table 3. Hazard Ratios for Cardiac and Overall Deaths by Thyroid Statusa
Variable
Euthyroidism
(n = 1905)
Subclinical Hypothyroidism
(n = 208)
Subclinical Hyperthyroidism
(n = 98)
Low T3
(n = 910)
Cardiac deaths, No. (n = 147) 65 15 8 59
Hazard ratio (95% CI) 1 [Reference] 2.40 (1.36-4.21) 2.32 (1.11-4.85) 1.63 (1.14-2.33)
P valueb .02 .02 .007
Overall deaths, No. (n = 295) 140 27 9 119
Hazard ratio (95% CI) 1 [Reference] 2.01 (1.33-3.04) 1.22 (0.62-2.40) 1.57 (1.22-2.01)
P value .001 .56 .001
Abbreviations: CI, confidence interval; low T3, low triiodothyronine syndrome.
aSee the “Definition of Thyroid Status” subsection of the “Methods” section for thyroid category definitions. Factors included in the multivariate model were
age, sex, ischemic and nonischemic heart disease, and levels of thyrotropin, free thyroxine, and free triiodothyronine.
bCompared with euthyroidism.
Table 4. Hazard Ratiosa for Cardiac Death by Thyroid Statusb in Ischemic and Nonischemic Heart Disease
Variable
Euthyroidism
(n = 1905)
Subclinical Hypothyroidism
(n = 208)
Subclinical Hyperthyroidism
(n = 98)
Low T3
(n = 910)
Ischemic heart disease
Patients, No. 999 101 46 565
Cardiac deaths, No. 43 12 7 9
Hazard ratio (95% CI) 1 [Reference] 3.1 (1.6-5.9) 3.5 (1.2-7.9) 1.6 (1.1-2.4)
P valuec . . . .001 .002 .05
Nonischemic heart disease
Patients, No. 906 107 52 345
Cardiac deaths, No. 22 3 1 20
Hazard ratio (95% CI) 1 [Reference] 1.2 (0.4-4.0) 0.6 (0.1-4.8) 1.8 (1.0-3.4)
P valuec . . . .76c .66 .05
Abbreviations: CI, confidence interval; low T3, low triiodothyronine syndrome.
aHazard ratios are corrected for age and sex.
bSee the “Definition of Thyroid Status” subsection of the “Methods” section for thyroid category definitions.
cCompared with euthyroidism.
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based studies only, where individuals were free of any
recognized cardiac disease,14,24,25 and (2) the small num-
ber of individuals with mild hyperthyroidism enrolled in
previous studies may have limited their ability to detect
the effect of SCT on cardiovascular outcome.14,25 In the
present study the SCT prevalence (3.1%) was smaller
than that of SCH (6.6%), as expected7; a lower power in
these data are, however, unlikely because this study
included almost 2 times more patients with SCT, with
more cardiac deaths than each of the 2 cited population-
based studies.14,25
From a pathophysiologic point of view, the present
observation of a significant increase in cardiac mortality
in cardiac patients with SCT should not be considered a
surprising finding; SCT has relevant unfavorable effects
on cardiacmorphologic features and function, blood pres-
sure, resting heart rate,18 and the performance of left ven-
tricular systolic function during exercise.
LOW TRIIODOTHYRONINE SYNDROME
It has already been reported that low T3 is an indepen-
dent predictor of death in cardiac patients.10-12 The pre-
sent results expand the previous findings and provide ad-
ditional evidence regarding the association between low
T3 andmortality in cardiac patients; this was possible be-
cause of the large cohort of enrolled patients with low
T3, the number of registered events, and the length of fol-
low-up of the present study. Overall, the biologically ac-
tive thyroid hormone triiodothyronine is a critical de-
terminant of cardiac function.5,6 For this reason the
progressive decrease in triiodothyronine levels, as ob-
served in low T3, may be part of the pathologic pro-
cesses leading to a progressive disturbance of the car-
diovascular system. Data in favor of this interpretation
have been emerging in recent years; on the contrary, the
alternative hypothesis of an adaptive and protective effect
of decreased triiodothyronine levels, at least in cardiac
patients, has become questionable.26 Another possible in-
terpretation is that low T3 is a marker of poor health that
is not causally related to cardiovascular disease. Indeed,
cardiac and noncardiac deaths are similarly increased in
patients with low T3.
LIMITATIONS
The major limitation of the present study is the lack of
information about follow-up thyroid function tests. How-
ever, the use of thyroid function tests obtained at a single
point in time is a limitation of all major published stud-
ies examining the relationship between endogenous thy-
roid dysfunction and cardiovascular disease.11,12,14,15,20-25
Nevertheless, of all patients with mild hypothyroidism,
only 2% to 5% per year will progress to overt hypothy-
roidism. At the same time, it is well known that few pa-
tients with serum thyrotropin levels between 0.1 and 0.45
mIU/L and less than 2% per year of those with levels less
than 0.1mIU/L progress to overt hyperthyroidism.7Other
limitations are the lack of nonfatal cardiovascular events,
possiblemisclassification of causes of death based ondeath
certificates, and lack of analysis by thyrotropin levels be-
cause of the small number of events.
In summary, a clear association between an in-
creased risk of death and the presence of mild thyroid
dysfunction has been documented in a large cohort of
cardiac patients. The potential clinical impact of thy-
roid dysfunction on cardiac patients is important if one
considers the high incidence of a mildly altered thyroid
hormone pattern in the cardiac population (38.9% of
total), as observed in this study.
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Correction
Error in Acknowledgments. In the Original Investiga-
tion by Jha et al titled “Concentration andQuality of Hos-
pitals That Care for Elderly Black Patients,” published
in the June 11, 2007, issue of theArchives (2007;167[11]:
1177-1182), the Funding/Support information para-
graph in the acknowledgments section was missing and
should have read as follows: “Funding/Support: This
studywas supported by the RobertWood Johnson Foun-
dation, Princeton,New Jersey.” The online version of this
article was corrected on June 11, 2007.
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